Enveric Biosciences Inc
ENVBEnveric Biosciences Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech burning 7.7M TTM cash with only 3.8M remaining - ~6 month runway without dilution[Cash and Equivalents]
- Market cap of 142K vs book value of 3.5M yields P/B of 0.04x - trading at 96% discount to tangible assets[Price to Book Ratio]
- R&D spend of 3.4M TTM is just 7.5% of industry median (45M) - minimal pipeline investment capacity[Research and Development]
Watch Triggers
- Cash and Equivalents: Falls below 2M or rises above 10M — Below 2M = imminent dilution; above 10M = successful raise extending runway
- Shares Outstanding: Increases >50% from 26K base — Signals magnitude of dilution - each doubling halves existing holder value
- Research and Development: Quarterly spend exceeds 1.5M — Would indicate accelerated pipeline activity but faster cash depletion
Bull Case
Negative EV of -3.6M means cash exceeds market cap - any pipeline success creates asymmetric upside from near-zero base
Zero debt (D/E: 0) and 3.3M working capital provide clean balance sheet for potential strategic transaction
Bear Case
6-month cash runway with -7.7M annual burn guarantees dilution; 26K shares could multiply 10x+ to fund operations
R&D of 3.4M is insufficient for meaningful clinical progress - underfunded vs 45M industry median
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ENVB's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent dilution or reverse split required within 6 months to fund operations
- Cash burn of 7.7M/year vs 3.8M cash
- Zero revenue generation
- 1.1M raised TTM insufficient
Extreme valuation discount suggests market pricing in near-certain failure or massive dilution
- P/B of 0.04x vs positive equity
- Negative enterprise value (-3.6M)
Public Strategies Rankings
See how Enveric Biosciences Inc ranks across different investment strategies.
Leverage ENVB's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
ENVB Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$136,780 | — | ||
$-3.62M | — | ||
0.00 | — | ||
$0 | — | ||
$1,390.00 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-7.67M | — | ||
-2.6 | +45.9% | — | |
Beta 5Y (Monthly) | unknown | — |
ENVB Dividend History
ENVB Stock Splits
ENVB SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/14/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
03/28/25 | 12/31/24 | Unknown | |
11/14/24 | 09/30/24 | 10-Q | |
08/12/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
03/26/24 | 12/31/23 | 10-K | |
11/13/23 | 09/30/23 | 10-Q | |
08/11/23 | 06/30/23 | 10-Q | |
05/15/23 | 03/31/23 | 10-Q | |
03/31/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/12/22 | 06/30/22 | 10-Q | |
05/13/22 | 03/31/22 | 10-Q | |
03/31/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
05/17/21 | 03/31/21 | 10-Q | |
04/01/21 | 12/31/20 | 10-K | |
11/16/20 | 09/30/20 | 10-Q | |
08/14/20 | 06/30/20 | 10-Q | |
05/15/20 | 03/31/20 | 10-Q | |
03/25/20 | 12/31/19 | 10-K | |
11/08/19 | 09/30/19 | 10-Q | |
08/14/19 | 06/30/19 | 10-Q | |
05/14/19 | 03/31/19 | 10-Q | |
03/26/19 | 12/31/18 | 10-K | |
11/14/18 | 09/30/18 | 10-Q | |
08/14/18 | 06/30/18 | 10-Q | |
05/15/18 | 03/31/18 | 10-Q | |
04/02/18 | 12/31/17 | 10-K | |
11/13/17 | 09/30/17 | 10-Q | |
08/14/17 | 06/30/17 | 10-Q | |
05/12/17 | 03/31/17 | 10-Q | |
03/31/17 | 12/31/16 | 10-K | |
11/14/16 | 09/30/16 | 10-Q | |
08/12/16 | 06/30/16 | 10-Q | |
05/15/17 | 03/31/16 | 10-Q/A | |
05/16/16 | 03/31/16 | 10-Q | |
11/23/15 | 09/30/15 | 10-Q | |
08/12/16 | 06/30/15 | 10-Q | |
08/14/15 | 06/30/15 | 10-Q | |
05/14/15 | 03/31/15 | 10-Q | |
03/31/15 | 12/31/14 | 10-K | |
11/14/14 | 09/30/14 | 10-Q/A | |
11/13/14 | 09/30/14 | 10-Q | |
08/11/14 | 06/30/14 | 10-Q | |
05/07/14 | 03/31/14 | 10-Q | |
03/28/14 | 12/31/13 | 10-K | |
11/06/13 | 09/30/13 | 10-Q | |
11/14/14 | 09/30/13 | 10-Q/A | |
08/01/13 | 06/30/13 | 10-Q | |
05/02/13 | 03/31/13 | 10-Q | |
05/08/14 | 03/31/13 | 10-Q/A | |
02/28/13 | 12/31/12 | 10-K | |
11/13/12 | 09/30/12 | 10-Q | |
08/01/12 | 06/30/12 | 10-Q | |
05/03/12 | 03/31/12 | 10-Q | |
03/07/12 | 12/31/11 | 10-K | |
11/14/11 | 09/30/11 | 10-Q | |
08/02/11 | 06/30/11 | 10-Q | |
05/16/11 | 03/31/11 | 10-Q | |
05/10/12 | 03/31/11 | 10-Q/A | |
03/07/11 | 12/31/10 | 10-K | |
11/15/10 | 09/30/10 | 10-Q | |
08/13/10 | 06/30/10 | 10-Q | |
05/17/10 | 03/31/10 | 10-Q | |
03/30/10 | 12/31/09 | 10-K | |
11/23/09 | 09/30/09 | 10-Q | |
08/13/09 | 06/30/09 | 10-Q | |
05/14/09 | 03/31/09 | 10-Q | |
12/31/08 | 12/31/08 | Unknown | -- |
11/12/08 | 09/30/08 | 10-Q | |
08/13/08 | 06/30/08 | 10-Q | |
05/14/08 | 03/30/08 | Unknown | -- |
03/31/08 | 12/31/07 | 10-K | |
11/09/07 | 09/30/07 | 10-Q | |
08/10/07 | 06/30/07 | 10-Q | |
05/10/07 | 03/30/07 | Unknown | -- |
03/29/07 | 12/31/06 | 10-K | |
11/14/06 | 09/30/06 | 10-Q | |
08/14/06 | 06/30/06 | 10-Q | |
05/15/06 | 03/30/06 | Unknown | -- |
03/30/06 | 12/31/05 | 10-K | |
11/07/05 | 09/30/05 | 10-Q | |
08/12/05 | 06/30/05 | 10-Q | |
05/12/05 | 03/30/05 | Unknown | -- |
03/30/05 | 12/31/04 | 10-K | |
11/12/04 | 09/30/04 | 10-Q | |
08/09/04 | 06/30/04 | 10-Q | |
05/13/04 | 03/30/04 | Unknown | -- |
03/22/04 | 12/31/03 | 10-K | |
11/12/03 | 09/30/03 | 10-Q | |
08/12/03 | 06/30/03 | 10-Q | |
05/13/03 | 03/30/03 | Unknown | -- |
03/27/03 | 12/31/02 | 10-K | |
11/13/02 | 09/30/02 | 10-Q | |
08/14/02 | 06/30/02 | 10-Q | |
05/14/02 | 03/30/02 | Unknown | -- |
03/28/02 | 12/31/01 | 10-K405 | |
11/13/01 | 09/30/01 | 10-Q | |
08/13/01 | 06/30/01 | 10-Q | |
05/11/01 | 03/30/01 | Unknown | -- |
03/28/01 | 12/31/00 | 10-K405 | |
11/07/00 | 09/30/00 | 10-Q | |
08/02/00 | 06/30/00 | 10-Q | |
05/09/00 | 03/30/00 | Unknown | -- |